PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
February 11, 2026Infection and Immunity0 citationsOpen Access

Post-TB lung disease: pathogenesis, host-directed therapies, and the C3HeB/FeJ model for pre-clinical advances

BOBoatema Ofori-AnyinamBNBrian NyiroDSDylan Sheerin

Key Points

  • To explore the mechanisms of post-TB lung disease (PTLD) and assess potential host-directed therapies.
  • Review of the global burden of PTLD and related chronic lung diseases.
  • Evaluation of host-directed therapies as possible treatments.
  • Discussion of the C3HeB/FeJ mouse model's role in pre-clinical research.
  • PTLD significantly affects the long-term respiratory health of individuals previously treated for TB.
  • Host-directed therapies show promise for improving outcomes in PTLD.
  • The C3HeB/FeJ model offers a valuable approach for advancing PTLD research.

Abstract

ABSTRACT More than half of the people with microbiologically cured tuberculosis (TB) present with post-TB lung disease (PTLD). PTLD compromises long-term respiratory health and adds to the global burden of chronic lung diseases. Despite its prevalence, the mechanisms driving tissue damage in TB are not well understood. In this review, we discuss the global burden of PTLD, evaluate host-directed therapies as promising interventions, and highlight the C3HeB/FeJ mouse model as a powerful tool for advancing pre-clinical PTLD research.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Ofori-Anyinam et al. (2026) studied this question.

synapsesocial.com/papers/698c1c46267fb587c655e93ahttps://doi.org/10.1128/iai.00523-24
Ask AI
Helpful
Bookmark
Share
View Full Paper